Post-treatment with the PPAR-γ agonist pioglitazone inhibits inflammation and bacterial growth during Klebsiella pneumonia
Open Access
- 19 August 2021
- journal article
- research article
- Published by Springer Nature in Respiratory Research
- Vol. 22 (1) , 1-4
Abstract
Agonists of peroxisome proliferator-activated receptor (PPAR)-γ have been suggested as potential adjuvant therapy in bacterial pneumonia because of their capacity to inhibit inflammation and enhance bacterial clearance. Previous studies only assessed the effects of pretreatment with these compounds, thereby bearing less relevance for the clinical scenario. Moreover, PPAR-γ agonists have not been studied in pneumonia caused by Klebsiella pneumoniae, a common human respiratory pathogen of which antibiotic treatment is hampered by increasing antimicrobial resistance. Here we show that administration of the PPAR-γ agonist pioglitazone 6 or 8 h after infection of mice with a highly virulent strain of Klebsiella pneumoniae via the airways results in reduced cytokine and myeloperoxidase levels in the lungs at 24 h after infection, as well as reduced bacterial growth in the lungs and decreased dissemination to distant organs at 42 h post-infection. These results suggest that pioglitazone may be an interesting agent in the treatment of Klebsiella pneumonia.Keywords
Funding Information
- ZonMw (50-52900-98-201)
- FAPESP (2019/02224-0)
This publication has 16 references indexed in Scilit:
- Platelet glycoprotein VI aids in local immunity during pneumonia-derived sepsis caused by gram-negative bacteriaBlood, 2018
- Klebsiella pneumoniae: Going on the Offense with a Strong DefenseMicrobiology and Molecular Biology Reviews, 2016
- Enhanced Clearance of Pseudomonas aeruginosa by Peroxisome Proliferator-Activated Receptor GammaInfection and Immunity, 2016
- PPARγin Bacterial Infections: A Friend or Foe?PPAR Research, 2016
- Aetiology of hospital-acquired pneumonia and trends in antimicrobial resistanceCurrent Opinion in Pulmonary Medicine, 2014
- PPARγ signaling and metabolism: the good, the bad and the futureNature Medicine, 2013
- Systemic Analysis of PPARγ in Mouse Macrophage Populations Reveals Marked Diversity in Expression with Critical Roles in Resolution of Inflammation and Airway ImmunityThe Journal of Immunology, 2012
- The thiazolidinedione ciglitazone reduces bacterial outgrowth and early inflammation during Streptococcus pneumoniae pneumonia in mice*Critical Care Medicine, 2009
- Macrophage-specific PPARγ controls alternative activation and improves insulin resistanceNature, 2007
- Stimulatory Effects of Peroxisome Proliferator-Activated Receptor-on FcReceptor-Mediated Phagocytosis by Alveolar MacrophagesPPAR Research, 2007